Search Results

ANGLE plc announces unaudited preliminary results for the year ended 31 December 2023.

ANGLE plc is pleased to announce its participation at the 2024 Annual Congress of the European Association for Cancer Research being held in Rotterdam, Netherlands from 10 to 13 June 2024.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.

ANGLE plc is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2023, and the Notice of Annual General Meeting within it, have been posted to shareholders, and are available on the Company’s website.

ANGLE plc is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer patients.

ANGLE plc is pleased to announce its participation at the 14th European Breast Cancer Conference being held in Milan, Italy on 20 to 22 March 2024.